For the year ending 2025-12-31, BHVN had $130,237K increase in cash & cash equivalents over the period. -$610,153K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -738,822 |
| Non-cash share-based compensation | 112,361 |
| Acquisition of ipr&d asset | 0 |
| Depreciation and amortization | 9,922 |
| Issuance of common shares as payment for license agreement | 4,844 |
| Change in fair value of notes payable | -8,700 |
| Obligation to issue common shares as payment for license agreements and other arrangements | 0 |
| Fair value of forward contract and derivative liabilities under license agreement | 0 |
| Change in fair value of forward contract and derivative liabilities | -9,426 |
| Issuance of warrant under license agreement | 0 |
| Other non-cash items | -174 |
| Prepaid expenses, income tax receivable, and other current and non-current assets | -3,531 |
| Accounts payable | -6,386 |
| Accrued expenses and other current and non-current liabilities | 4,212 |
| Net cash used in operating activities | -609,438 |
| Proceeds from maturities of marketable securities | 570,000 |
| Proceeds from sales of marketable securities | 0 |
| Purchases of marketable securities | 266,875 |
| Purchases of property and equipment | 715 |
| Cash acquired from acquisition of ipr&d asset | 0 |
| Other investing activities | 1,849 |
| Net cash provided by (used in) investing activities | 300,561 |
| Change in restricted cash due to former parent | 0 |
| Proceeds from issuance of notes payable | 250,000 |
| Proceeds from issuance of common shares | 189,175 |
| Payments of issuance costs | 1,697 |
| Proceeds from issuance of common shares under 2022 equity incentive plan and 2022 employee share purchase plan | 1,833 |
| Other financing activities | -194 |
| Net cash provided by financing activities | 439,117 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | -3 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 130,237 |
| Cash, cash equivalents and restricted cash at beginning of period | 102,542 |
| Cash, cash equivalents and restricted cash at end of period | 232,779 |
Biohaven Ltd. (BHVN)
Biohaven Ltd. (BHVN)